Please note, this OEL/ADE monograph also applies to dapoxetine hydrochloride (CAS RN 129938-20-1). Dapoxetine is a selective serotonin reuptake inhibitor (SSRI) used to treat premature ejaculation. It is marketed around the world, but not in the United States. The ejaculatory reflex is regulated by multiple neurotransmitter systems at the spinal and supra-spinal levels and the serotonergic system plays a major role in the reflex. Dapoxetine is proposed to delay ejaculation through potential of the actions of serotonin. By inhibiting the serotonin transporter, concentrations of the neurotransmitter are increase in the synapse and extracellular space.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Dapoxetine, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.